The first EU JCA decoded: Key lessons for future HTA success
The first EU Joint Clinical Assessment is now a reality, and it is already offering valuable insights into how EU Health Technology Assessment Regulation may shape future evidence requirements, market access strategy, and local pricing and reimbursement decision-making.
Join Simon-Kucher experts for a focused webinar exploring the first JCA through the case of tovorafenib in paediatric low-grade glioma. Drawing on our in-depth reverse-engineering analysis, we will unpack how PICO scoping and evidence appraisal appear to work in practice, and what this means for manufacturers preparing for future EU HTA submissions.
Beyond the published report, the session will highlight the strategic implications for evidence planning, stakeholder engagement, and local P&R readiness in an evolving regulatory environment.
Participants will learn more about:
